Publications by authors named "Samar K Mann"
Expert Opin Pharmacother
August 2024
Article Synopsis
- Randomized clinical trials indicate that BTK inhibitors (BTKis) may heighten the risk of infectious diseases (IDs), prompting the need for systematic analysis based on both clinical practices and trial data.
- A thorough review of peer-reviewed sources from 2014 to 2023 was conducted to assess ID morbidity in patients taking BTKis, taking into account immune defects present in patients with indolent B-cell lymphomas.
- The findings highlight a significant association between BTKi usage and increased incidents of upper respiratory infections and invasive fungal infections, underscoring the need for better understanding and management of these risks to enhance patient outcomes.
